Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels. | Available online at http content 9 5 E20 University of Pittsburgh Department of Critical Care Medicine Evidence-Based Medicine Journal Club EBM Journal Club Section Editor Eric B. Milbrandt MD MPH Journal club critique Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels Eliseo Rondon1 and Ramesh Venkataraman2 1 Clinical Fellow Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA 2 Assistant Professor Department of Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA Published online 5 August 2005 This article is online at http content 9 5 E20 2005 BioMed Central Ltd Critical Care 9 E20 DOI cc3798 Expanded Abstract Citation Panacek EA Marshall JC Albertson TE Johnson DH Johnson S MacArthur RD Miller M Barchuk WT Fischkoff S Kaul M Teoh L Van Meter L Daum L Lemeshow S Hicklin G Doig C Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F ab 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004 32 2173-2182 1 . Hypothesis Afelimomab a fragment of murine monoclonal antibody to human TNF-a reduces 28-day all-cause mortality in patients with severe sepsis and elevated serum IL-6 levels. Methods Design Prospective randomized double-blind placebo-controlled multi-center phase III clinical trial. Setting One hundred fifty-seven intensive care units in the United States and Canada. Subjects 2 634 patients with severe sepsis secondary to documented infection of whom 998 had elevated IL-6 levels. Intervention Patients were stratified into two groups by means of a rapid qualitative interleukin-6 test kit designed to identify patients with serum interleukin-6 levels above test positive or below test negative approximately 1000 pg mL. Of the 2 634 patients 998 were stratified into the test-positive group 1 636 into the .
